BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank-check company formed to identify and complete a business combination in the biopharmaceutical and life sciences sector. The company completed its initial public offering in 2021, targeting innovative healthcare businesses with strong commercial or clinical-stage prospects. In September 2023, BioPlus filed a Form 425 with the Securities and Exchange Commission, a communication type associated with an announced business combination, signaling active progress toward a merger target at that time. The SPAC was structured under the sponsorship of BioPlus Holdings, reflecting management's focus on healthcare deal-making experience. For full filing history, deal timelines, voting data, and target details on BioPlus Acquisition Corp. and hundreds of other SPACs, create a free account at SpacDesk.